Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NMT1 | P30419 | 1/20 | 0.58 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.57 |
| ▸ | PIP4K2A | P48426 | 2/20 | 0.56 |
| ▸ | PIP4K2B | P78356 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | TGM2 | P21980 | 1/20 | 0.53 |
| ▸ | MMP1 | P03956 | 4/20 | 0.53 |
| ▸ | MMP2 | P08253 | 4/20 | 0.53 |
| ▸ | MMP9 | P14780 | 4/20 | 0.53 |
| ▸ | EGFR | P00533 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | CDK14 | O94921 | 1/20 | 0.47 |
| ▸ | CCNY | Q8ND76 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20764166 | 0.87 | CDK14 (0.47) | PIP4K2APIP4K2BALDH1A1EGFRLMNA | |
| SCHEMBL13067824 | 0.86 | EGFR (0.47) | DDAH1PIP4K2APIP4K2BALDH1A1EGFR | |
| SCHEMBL13389249 | 0.85 | EGFR (0.55) | PIP4K2APIP4K2BALDH1A1TGM2MMP1 | |
| SCHEMBL17141876 | 0.84 | PIP4K2A (0.50) | NMT1PIP4K2APIP4K2BALDH1A1EGFR | |
| SCHEMBL22106124 | 0.84 | CDK14 (0.46) | PIP4K2APIP4K2BALDH1A1MMP1MMP2 | |
| SCHEMBL23336402 | 0.84 | CDK14 (0.46) | PIP4K2APIP4K2BALDH1A1EGFRSMN1; SMN2 | |
| SCHEMBL16665568 | 0.84 | PIP4K2A (0.50) | NMT1PIP4K2APIP4K2BALDH1A1EGFR | |
| SCHEMBL18113964 | 0.83 | KDM4E (0.49) | DDAH1PIP4K2APIP4K2BALDH1A1SMN1; SMN2 | |
| SCHEMBL20093336 | 0.83 | EGFR (0.56) | PIP4K2APIP4K2BALDH1A1EGFRLMNA | |
| SCHEMBL23336317 | 0.83 | KDM4E (0.49) | DDAH1PIP4K2APIP4K2BALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023104035-A1 | SUBSTITUTED MONOCYCLIC OR BICYCLIC HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | 英矽智能科技(上海)有限公司 | 2023-06-15 | — | — | WO | disclosed |
| EP-3057956-B1 | POLYCYCLIC INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | DANA FARBER CANCER INST INC (US) | 2021-05-05 | — | — | EP | disclosed |
| WO-2018098367-A1 | INHIBITORS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASES AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-05-31 | — | — | WO | disclosed |
| US-20160264554-A1 | POLYCYCLIC INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | DANA-FARBER CANCER INSTITUTE, INC. | 2016-09-15 | — | — | US | disclosed |
| WO-2015058140-A1 | POLYCYCLIC INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2015-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160264554-A1 | POLYCYCLIC INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | CDK13, CDK3, CDK12 | NMT1 2593/4885DDAH1 4099/4885PIP4K2A 579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.